Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vincera Pharma, Inc.

0.6202
-0.0989-13.75%
Volume:780.29K
Turnover:494.37K
Market Cap:1.39M
PE:-0.04
High:0.7000
Open:0.6687
Low:0.5910
Close:0.7191
Loading ...

Company Profile

Company Name:
Vincera Pharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
42
Office Location:
260 Sheridan Avenue,Suite 400,Palo Alto,California,United States
Zip Code:
94306
Fax:
- -
Introduction:
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Directors

Name
Position
Andrew McDonald
Chairman, Chief Executive Officer and Director
Barry Dennis
Independent Director
Brian Schwartz
Independent Director
David Dobkin
Chief Financial Officer and Director
John Ziegler
Independent Director
Jonas Grossman
Independent Director
Karin Walker
Independent Director
Michael Rice
Chief Operating Officer and Director

Shareholders

Name
Position
Andrew McDonald
Chairman, Chief Executive Officer and Director
Michael Rice
Chief Operating Officer and Director
David Dobkin
Chief Financial Officer and Director